On July 23, INSILICO rose 5.46% in regular trading, trading at 47.98 HKD/share, with turnover of approximately HKD 108 million.

On the news front, the company has secured multiple heavyweight strategic partnerships since early July. Key developments include a deal with Takeda Pharmaceutical valued up to USD 600 million encompassing a USD 60 million upfront payment plus milestone payments, a multi-faceted alliance with Bora Pharmaceuticals with potential value exceeding USD 2.5 billion, and a CNS drug discovery collaboration with CMS featuring milestone payments up to approximately RMB 1.2 billion. Additionally, the company's self-developed drug Rentosertib has initiated a Phase III clinical trial for idiopathic pulmonary fibrosis. During the World Artificial Intelligence Conference, the company also participated as a strategic investor in Yuan Ma Zhi Yao's Pre-A round and formed a tripartite collaboration targeting in-vivo CAR-T and mRNA drug development. The AI pharmaceutical sector continues to see elevated sentiment as commercialization milestones accelerate across the industry.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)